Tristel Share Discussion Threads

[brummy_git] 24/2/2016 08:56

New research out today from Equity Development

hxxp://www.equitydevelopment.co.uk/doc/1457.pdf

[glaws2] 24/2/2016 08:53

Very disappointing results and outlook. In two months the rate of revenue growth for future years has been slashed by more than a third from 15% to less than 10%.

Statutory results significantly behind comparatives due to the share based payments. On the bright side they are expected to reduce from the £1m in this period to £100-200k per annum in future.

Lets hope the presentations give some insight in future upsides.

[mfhmfh] 24/2/2016 08:51

Looks like significant future growth will come from overseas rather than UK sales which is to be expected. Management seem to be concentrating on this, as Paul Swinney said:

'Our international expansion continues with many regulatory approvals awaited, not only in healthcare markets in which we already sell, but also in countries in which we have no presence. This includes the United States.'

SP might not do much until Q3/Q4 this year but should be worth the wait when it does.

IMHO

[mach100] 24/2/2016 08:44

The sell-off is way overdone. Caught me on the hop as I wanted to offload some if we had less than stellar results. I think the USA will be the making of the company with 250 to 300p possible but I also expected this to hit the buffers when growth slowed/ It is clawing back now from 126p bid so buyers are coming in on weakness.

[source] 24/2/2016 08:34

Nice chart Piedro - to be honest this year to me always sounded like an investment year based on previous management statements i.e. ERP, USA, Euro Investments & New Bio regs etc

These are nicely reflected in your chart. If Tristel get these things right then its growth in furture should be quite well supported.

From todays reaction though it seems some were expecting this year to blow out its longstanding EPS forecasts to be exceeded, which seemed unreasonable to me based on where TSTL is with its developement/investment cycle. However it may well now drop as a result of these types of expectations in the market.

Regards,
Source.

[shanklin] 24/2/2016 08:29

Its a shame, the explanation re share-based payments provided no commentary on the potential situation going forward.

[apad] 24/2/2016 08:24

ps
agree about costs.
pps
Could be some useful share weakness as the headline figures might put it off the radar.
ppps
Like the divy increase.

[apad] 24/2/2016 08:22

A couple of negatives in TSTL - EU regulation driving the withdrawal of non CHLORINE DIOXIDE PRODUCTS, and more to come. Revenue only up 8%. I presume the two points are linked as profitability is up 32%.
apad

[gdjs100] 24/2/2016 08:18

Turnover marginally up, but as legacy non ClO2 products are dropped this will act as a drag on turnover (but margins improve, as was the case).You have included the share based payments charge in your costs too. As stated in the report, the charge for H1 is exceptionally large and won't continue this high.

[davr0s] 24/2/2016 08:14

Not sure that update warrants a 11% drop

[piedro] 24/2/2016 07:44

I like to draw the 6 monthly chart ....



- turnover flat / costs jumped

AIMHO, BWDIK.

[source] 24/2/2016 07:24

Seems steady progress in the interims. Margins up, overseas sales up strongly and a healthy dividend hike. USA application progressing ok (most planned in second half). UK sales were largely flat though and overall sales growth was 8% (less than the past). Cash generation and level were strong exiting Dec at £4.1m which seems good. Regards,Source.

[tmfmayn] 22/2/2016 14:26

Appears the TSTL execs will be busy on Thursday

Davidosh has arranged an 11:30am company presentation of his own:

The webinar is at 1:15pm (30 mins presentation plus Q&As)

Then the evening gig at 5:45pm.

Anyone attending all three?

[davidosh] 22/2/2016 12:50

Just a reminder....

A briefing for all investors will take place on Thursday 25 February at No.1 Cornhill, London, EC3V 3ND from 5.30pm for a 5.45pm start, and will be followed by drinks and canapés.

If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email [e-mail]

[source] 22/2/2016 07:16

EC thanks. I'm also hoping for some positive USA progress. And maybe another special dividend!Hopefully see some of you on Thursday. Regards,Source.

[effortless cool] 22/2/2016 06:59

Glaws2,

I model the income statement, balance sheet and cash flow statement in their entirety, and those are the numbers that come out. Spuriously accurate, I agree.

Pleased to hear we're in the same ballpark.

[glaws2] 22/2/2016 06:30

That's one accurate forecast EC :). My revenue and PTP forecasts are very similar - but not to so many decimal points

[effortless cool] 21/2/2016 22:32

My forecasts for the interims:

Revenue £8,119k
PTP £1,479k
Net cash £5,059k
EPS 2.81p
DPS 0.60p

[mach100] 21/2/2016 22:16

You coming to the post results presentation Piedro? I will be there and happy to put any questions. You can tweet me if you like. I take it source will be there. I am hoping the good run doesn't come to an end so will have a beady eye on results Wednesday. I am interested in progress in the US for a 2017 entry and more news on Germany etc.

[source] 21/2/2016 07:09

C u there metis!

Regards,
Source.

[piedro] 18/2/2016 06:38

Reply from Paul ...

Thank you P.,
You must have 20:20 vision.
Interims announcement is next Wednesday.
Regards,
Paul

- DYOC

[piedro] 17/2/2016 16:20

TMFMayn,
I think that the company should clarify the position.
I put the question at the last webinar but it was not well answered

[effortless cool] 17/2/2016 16:05

£91m is hardly an exciting target market.